
USD
+$0.00
(+0.00%
)At Close (As of Oct 24, 2025)
$585.72M
Market Cap
-
P/E Ratio
-2.23
EPS
$2.72
52 Week High
$0.85
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $37M |
| Total Revenue | $154M |
| Cost Of Revenue | $117M |
| Costof Goods And Services Sold | $117M |
| Operating Income | -$474M |
| Selling General And Administrative | $175M |
| Research And Development | $135M |
| Operating Expenses | $512M |
| Investment Income Net | - |
| Net Interest Income | -$13M |
| Interest Income | - |
| Interest Expense | $13M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $53M |
| Income Before Tax | -$310M |
| Income Tax Expense | $316K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$310M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$296M |
| Ebitda | -$243M |
| Net Income | -$310M |
| Field | Value (USD) |
|---|---|
| Total Assets | $1.3B |
| Total Current Assets | $496M |
| Cash And Cash Equivalents At Carrying Value | $55M |
| Cash And Short Term Investments | $55M |
| Inventory | $59M |
| Current Net Receivables | $28M |
| Total Non Current Assets | $765M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $390M |
| Intangible Assets Excluding Goodwill | $390M |
| Goodwill | $318M |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $335M |
| Other Current Assets | $19M |
| Other Non Current Assets | - |
| Total Liabilities | $754M |
| Total Current Liabilities | $66M |
| Current Accounts Payable | $17M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $20M |
| Total Non Current Liabilities | $688M |
| Capital Lease Obligations | $25M |
| Long Term Debt | $647M |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $672M |
| Other Current Liabilities | $16M |
| Other Non Current Liabilities | $19M |
| Total Shareholder Equity | $507M |
| Treasury Stock | - |
| Retained Earnings | -$2.1B |
| Common Stock | $294K |
| Common Stock Shares Outstanding | $288M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$206M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $53M |
| Capital Expenditures | $6.2M |
| Change In Receivables | - |
| Change In Inventory | -$8.3M |
| Profit Loss | - |
| Cashflow From Investment | $124M |
| Cashflow From Financing | -$43M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$310M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $37M |
| Total Revenue | $154M |
| Cost Of Revenue | $117M |
| Costof Goods And Services Sold | $117M |
| Operating Income | -$474M |
| Selling General And Administrative | $175M |
| Research And Development | $135M |
| Operating Expenses | $512M |
| Investment Income Net | - |
| Net Interest Income | -$13M |
| Interest Income | - |
| Interest Expense | $13M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $53M |
| Income Before Tax | -$310M |
| Income Tax Expense | $316K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$310M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$296M |
| Ebitda | -$243M |
| Net Income | -$310M |
Sector: HEALTHCARE
Industry: MEDICAL DEVICES
Pacific Biosciences of California, Inc. (PACB) is a leading biotechnology company based in Menlo Park, California, specializing in cutting-edge genomic sequencing technologies that are revolutionizing the field. By providing high-resolution sequencing systems, PACB supports a range of applications from genetic research to personalized medicine, catering to the needs of researchers and healthcare professionals alike. With a robust focus on research and development and a growing suite of innovative products, PACB is well-positioned to capitalize on the rising demand for detailed genomic insights, making it a key player in the evolving life sciences landscape.